Insivio is an AI drug discovery company building a 7-program in-house pipeline across oncology and rare disease — every candidate computationally generated, IP-protected, and advancing toward pharma out-licensing.
Our agentic AI platform runs all programs through the same 5-stage discovery workflow — from target validation through patent filing — before any wet-lab spend.
We focus where unmet need is highest and computational design is most powerful.
Structure-based drug design, molecular docking, and AI-guided optimization produce candidates with validated targets, favorable ADMET profiles, and defensible IP positions — in indications eligible for FDA & EMA Orphan Drug Designation.
RNA interference candidates addressing disease-relevant genes where no small molecule solution exists. Advanced SORT-LNP delivery platforms reach target tissues with precision, opening therapeutic territory conventional discovery cannot access.
We own our drug candidates. Every program is computationally generated, IP-protected, and developed internally. Revenue comes from milestone payments and pharma royalties — not consulting.
Our discovery process was designed around agentic AI from day one — the platform is the R&D infrastructure, not a layer on top of an existing process.
Every program runs freedom-to-operate analysis before significant development investment. Patent strategy is concurrent with discovery — not downstream of it.
Orphan designation, IND strategy, and CMC readiness are considered at the program design stage — not at exit. Four of seven programs are FDA & EMA ODD-eligible.
More than 300 million people worldwide live with a rare disease. Fewer than 5% have an approved treatment. The barrier is not scientific — it is economic. Until now, the cost and complexity of drug discovery made rare disease programs financially unviable for all but the largest pharmaceutical companies.
By dramatically reducing the cost of computational discovery, Insivio builds robust, IP-protected programs in indications previously out of reach — and advances them toward Orphan Drug Designation with the scientific rigor regulators expect.
The same agentic AI infrastructure powering Insivio’s in-house pipeline is available to external researchers and health consumers.
End-to-end computational drug discovery for academic labs, rare disease foundations, and biotech teams. Small molecule and RNAi workflows, AI-orchestrated. Pharma-grade in silico pipelines at a fraction of enterprise cost.
Privacy-first biological age and longevity optimization platform. On-device AI processes your biomarkers and health data locally — your data never leaves your device. Personalized healthspan insights without surveillance.
Whether you are investing, licensing, or engaging in a regulatory capacity — we are open for conversation.
Insivio combines the capital efficiency of a technology company with the asset value of a pharmaceutical pipeline. Our AI platform generates proprietary candidates; our in-house programs are IP-protected, modality-diversified, and advancing toward preclinical milestones.
Request investor materials →Our pipeline of small molecule and RNAi candidates is developed with out-licensing and co-development in mind. Programs arrive at partnership discussions with ADMET profiles, IP filings, competitive landscape analysis, and a clear regulatory pathway.
Explore licensing →We are committed to proactive, transparent engagement with the FDA and EMA. Programs targeting rare indications are being advanced with Orphan Drug Designation as a foundational strategic objective under both FDA and EMA COMP procedures.
Regulatory enquiries →Whether you are an investor, pharma business development team, or regulatory professional — we are open for conversation.
Our programs arrive at partnership discussions documentation-ready: ADMET dossiers, IP filings, competitive landscape, and a clear regulatory pathway — reducing diligence time and de-risking early partnership decisions.
Fill in your details and our team will be in touch within 48 hours.